Abnormal Restriction Pattern of PIP Gene Associated with Human Primary Prostate Cancers
- Is TIG1 a New Tumor Suppressor in Prostate Cancer? Lotan, Reuben // JNCI: Journal of the National Cancer Institute;4/3/2002, Vol. 94 Issue 7, p469
Reports the identification of a gene whose decreased expression may contribute to the development and progression of prostate cancer. Use of a selective subtractive differential gene display; Induction of the gene by the synthetic retinoid tazarotene in human skin raft cultures; Indication made...
- Viral Based Gene Therapy for Prostate Cancer. Yi Lu // Current Gene Therapy;Jul2001, Vol. 1 Issue 2, p183
In the last few years, significant advances in gene therapy have been made as a result of advances in many areas of molecular and cell biology, including the improvement of both viral and nonviral gene delivery systems, discovery of new therapeutic genes, better understanding of mechanism of...
- New gene expression-based model predicts clinical PCa. Newman, Laura // Urology Times;May2002, Vol. 30 Issue 5, p11
Reports on a gene expression-based model predicting the behavior of prostate cancer in men in Bethesda, Maryland. Prediction of the recurrence of the tumor following prostatectomy; Percentage of the accuracy rate of the method; Gene expressions of the model.
- Targeting of adenoviral vectors for gene therapy of prostate cancer. Bangma, C H // Prostate Cancer & Prostatic Diseases;2000, Vol. 3 Issue 4, p308
The transduction of cytotoxic genes by adenoviral vectors into prostatic cells offers a new entity for the treatment of prostate cancer. Current adenoviral vectors cannot infect prostatic cells selectively, and expression of therapeutic genes is often too low to be efficient. Bispecific...
- Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Goessl, C; Müller, M; Miller, K // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS17
Although prostate specific antigen (PSA) represents a sensitive serum tumour marker for prostate cancer, its use is limited by an insufficient specificity. Therefore, DNA-based molecular tumour markers might increase specificity in the detection of primary and recurrent prostate cancer. The...
- Adenoviral mediated gene therapy for prostate cancer: studies on vector tropism and payload. Bangma, C H; Kraaij, R; Oomen, M H A; Th Van Rijswijk, A L C; de Ridder, C M A // Prostate Cancer & Prostatic Diseases;2000 Supplement 1, Vol. 3 Issue 4, pS5
Adenovirus (Ad5) mediated gene therapy for prostate cancer offers a new therapeutic modality. Payloads of various origins (cytotoxic, immunomodulatory, repair genes) have been applied in experimental settings and even in clinical phase I trials to alter tumour growth. We report here on in vitro...
- Evidence for an association between the SRD5A2 (type II steroid 5. Margiotti, K.; Sangiuolo, F.; De Luca, A.; Froio, F.; Pearce, C.L.; Ricci-Barbini, V.; Micali, F.; Bonaf\`e, M.; Franceschi, C.; Dallapiccola, B.; Novelli, G.; Reichardt, J.K.V. // Disease Markers;2000, Vol. 16 Issue 3/4, p147
We have investigated the contributions of three polymorphic markers in the SRD5A2 gene to prostate cancer in a group of Italian patients. We have genotyped cases and controls for a polymorphic (TA)
- CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. Cheng, Liang; Sun, Jian // JNCI: Journal of the National Cancer Institute;05/01/96, Vol. 88 Issue 9, p607
Seeks to establish a relevant ex vivo tumor model for gene therapy studies of human prostate cancer. Morphological characteristics and culture behavior of human primary prostate cancer CWR22 cells in the collagen gel culture system; Expression of transgenic cytokines in transfected CWR22 cells;...
- Gene therapy finds cracks in prostate cancer's defenses. Overmyer, Mac // Urology Times;Sep96, Vol. 24 Issue 9, p22
Discusses the use of gene therapy on prostate cancer. Comparison with battlefield tactics; Thymidine kinase and adenoviruses; Cell-specific therapy; Subverting cellular machinery.